Lemaitre Vascular Inc’s recently made public that its Director Jasinski Lawrence J unloaded Company’s shares for reported $90553.0 on Aug 12 ’25. In the deal valued at $92.78 per share,976 shares were sold. As a result of this transaction, Jasinski Lawrence J now holds 4,773 shares worth roughly $0.44 million.
Then, Roberts David B sold 10,815 shares, generating $999,173 in total proceeds. Upon selling the shares at $92.39, the President and Director now owns 17,976 shares.
Before that, Ross Bridget A sold 2,500 shares. Lemaitre Vascular Inc shares valued at $235,000 were divested by the Director at a price of $94.00 per share. As a result of the transaction, Ross Bridget A now holds 2,916 shares, worth roughly $0.27 million.
Barrington Research upgraded its Lemaitre Vascular Inc [LMAT] rating to an Outperform from a a Mkt perform in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who decreased its forecast for the stock in late February from “an Outperform” to “a Perform”. Barrington Research also remained covering LMAT and has decreased its forecast on February 28, 2025 with a “Mkt perform” recommendation from previously “an Outperform” rating. Wells Fargo started covering the stock on February 13, 2025. It rated LMAT as “an Equal weight”.
Price Performance Review of LMAT
On Friday, Lemaitre Vascular Inc [NASDAQ:LMAT] saw its stock fall -1.25% to $92.25. Over the last five days, the stock has lost -0.04%. Lemaitre Vascular Inc shares have risen nearly 3.86% since the year began. Nevertheless, the stocks have risen 0.12% over the past one year.
How much short interest is there in Lemaitre Vascular Inc?
A steep rise in short interest was recorded in Lemaitre Vascular Inc stocks on 2025-08-29, growing by 16972.0 shares to a total of 1.35 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 1.33 million shares. There was a rise of 1.26%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 15, 2024 when Cantor Fitzgerald began covering the stock and recommended ‘”a Neutral”‘ rating along with a $96 price target.
